Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Tiantan Biological Products Co., Ltd. (600161.SS)
Beijing, CN
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.65% | +1.20% | -3.76% | -12.24% | -22.65% | -12.24% | -25.16% | -33.21% | -38.08% | +78.80% | +2,163.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+1.8% ★ Q1'26: -15.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-29.5% Q1'26: -47.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3.9% Q1'26: -15.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+28.8% ★ Q1'26: +17.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+10.7% ★ Q1'26: +4.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.4% ★ Q1'26: -2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.08× ★ Q1'26: 0.12× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.62B
est: 2.63B (-38.5%)
|
2.14B
est: 2.09B (+2.3%)
|
2.48B
est: 1.50B (+65.1%)
|
2.93B
est: 2.78B (+5.4%)
|
3.28B
est: 3.48B (-5.6%)
|
3.45B
est: 3.44B (+0.1%)
|
4.11B
est: 4.11B (+0.1%)
|
4.26B
est: 4.27B (-0.1%)
|
5.18B
est: 5.33B (-2.8%)
|
6.03B
est: 6.03B (0.0%)
|
6.14B
est: 6.55B (-6.3%)
|
6.50B
6.05B – 6.91B
-0.8% YoY
|
7.08B
6.19B – 7.89B
+9.0% YoY
|
7.42B
7.41B – 7.43B
+4.8% YoY
|
| EBITDA |
489.20M
est: 969.19M (-49.5%)
|
661.68M
est: 769.26M (-14.0%)
|
940.68M
est: 553.69M (+69.9%)
|
980.84M
est: 1.02B (-4.2%)
|
1.15B
est: 1.28B (-10.2%)
|
1.18B
est: 1.27B (-6.7%)
|
1.31B
est: 1.51B (-13.2%)
|
1.45B
est: 1.57B (-7.5%)
|
1.95B
est: 2.44B (-20.0%)
|
2.78B
est: 2.77B (+0.4%)
|
2.22B
est: 3.00B (-26.1%)
|
2.98B
2.77B – 3.17B
-0.8% YoY
|
3.25B
2.84B – 3.62B
+9.0% YoY
|
3.40B
3.40B – 3.41B
+4.8% YoY
|
| EBIT |
293.38M
est: 859.66M (-65.9%)
|
446.20M
est: 682.33M (-34.6%)
|
772.16M
est: 491.11M (+57.2%)
|
850.82M
est: 908.16M (-6.3%)
|
1.02B
est: 1.14B (-10.0%)
|
1.05B
est: 1.12B (-6.6%)
|
1.17B
est: 1.34B (-12.5%)
|
1.29B
est: 1.39B (-7.2%)
|
1.71B
est: 1.85B (-7.6%)
|
2.47B
est: 2.09B (+18.3%)
|
1.77B
est: 2.27B (-22.2%)
|
2.25B
2.09B – 2.39B
-0.8% YoY
|
2.45B
2.14B – 2.73B
+9.0% YoY
|
2.57B
2.57B – 2.57B
+4.8% YoY
|
| Net Income |
9.98M
est: 198.36M (-95.0%)
|
256.89M
est: 283.38M (-9.3%)
|
1.17B
est: 1.19B (-1.1%)
|
509.48M
est: 562.70M (-9.5%)
|
611.09M
est: 681.00M (-10.3%)
|
639.01M
est: 724.10M (-11.8%)
|
760.01M
est: 793.07M (-4.2%)
|
880.92M
est: 937.88M (-6.1%)
|
1.11B
est: 1.27B (-12.6%)
|
1.55B
est: 1.46B (+6.4%)
|
1.09B
est: 1.34B (-18.9%)
|
1.29B
1.10B – 1.31B
-3.9% YoY
|
1.52B
991.75M – 1.67B
+18.0% YoY
|
1.62B
1.16B – 1.65B
+5.9% YoY
|
| SGA |
115.31M
est: 266.09M (-56.7%)
|
249.17M
est: 211.20M (+18.0%)
|
153.63M
est: 152.01M (+1.1%)
|
187.49M
est: 281.10M (-33.3%)
|
211.92M
est: 351.40M (-39.7%)
|
190.90M
est: 347.74M (-45.1%)
|
599.27M
est: 415.23M (+44.3%)
|
407.16M
est: 431.10M (-5.6%)
|
739.33M
est: 584.28M (+26.5%)
|
397.47M
est: 661.27M (-39.9%)
|
602.35M
est: 717.91M (-16.1%)
|
712.06M
662.86M – 756.88M
-0.8% YoY
|
776.01M
678.67M – 864.68M
+9.0% YoY
|
813.64M
812.49M – 814.79M
+4.8% YoY
|
| EPS |
0.01
est: 0.10 (-93.2%)
|
0.17
est: 0.14 (+19.1%)
|
0.78
est: 0.60 (+30.6%)
|
0.34
est: 0.28 (+20.0%)
|
0.59
est: 0.34 (+72.1%)
|
0.63
est: 0.36 (+72.8%)
|
0.67
est: 0.40 (+67.8%)
|
0.73
est: 0.47 (+54.6%)
|
0.56
est: 0.64 (-12.3%)
|
0.78
est: 0.78 (-0.6%)
|
0.55
est: 0.68 (-19.5%)
|
0.61
0.56 – 0.66
-10.2% YoY
|
0.70
0.50 – 0.84
+14.9% YoY
|
0.74
0.59 – 0.83
+4.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 1.16% | 930.3K | 0.68% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.11% | 40.6K | 0.65% |
| 3 | HSBC MSCI China A UCITS ETF HMCT.L | 0.10% | 131.1K | 0.30% |
| 4 | Samsung KODEX China CSI300 ETF 283580.KS | 0.05% | 102.9K | 0.12% |
| 5 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.04% | 6.4K | 0.65% |
| 6 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.03% | 24.1K | 0.55% |
| 7 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 198.7K | 0.19% |
| 8 | Franklin FTSE China ETF FLCH | 0.01% | 23.5K | 0.19% |
| 9 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 3.8K | 0.15% |
| 10 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 102.0K | 0.46% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ding Yu | Deputy General Manager | — | male |
| Hongqing Wang | Chief Financial Officer | — | male |
| Yana Liu | Deputy GM & Director | — | female |
| Yanlin He | Deputy GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600161.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
